Clinical Trial Update: Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

The Phase 1 study of SPX-101 in adults with advanced or refractory solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• SPX-101 (SPX-101)

Snippet

Sponsor: SparX Biotech(Jiangsu) Co., Ltd. | Conditions: Solid Tumors | Phase 1 | Status: WITHDRAWN